Details for Patent: 8,784,885
✉ Email this page to a colleague
Which drugs does patent 8,784,885 protect, and when does it expire?
Patent 8,784,885 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.
Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty-one patent family members in twenty-nine countries.
Summary for Patent: 8,784,885
| Title: | Controlled release preparation |
| Abstract: | A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. |
| Inventor(s): | Akiyama; Yohko (Osaka, JP), Kurasawa; Takashi (Osaka, JP), Bando; Hiroto (Osaka, JP), Nagahara; Naoki (Osaka, JP) |
| Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 12/839,054 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; Delivery; |
Drugs Protected by US Patent 8,784,885
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,784,885
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2002-301876 | Oct 16, 2002 |
| Japan | 2003-066336 | Mar 12, 2003 |
International Family Members for US Patent 8,784,885
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 041562 | ⤷ Sign Up | |||
| Argentina | 103296 | ⤷ Sign Up | |||
| Australia | 2003272098 | ⤷ Sign Up | |||
| Australia | 2009243408 | ⤷ Sign Up | |||
| Brazil | 0315142 | ⤷ Sign Up | |||
| Brazil | 122016030094 | ⤷ Sign Up | |||
| Brazil | PI0315142 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
